Fatty Acid Oxidation Disorders (FAODs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Fatty Acid Oxidation Disorders (FAODs) Market Outlook

Thelansis’s “Fatty Acid Oxidation Disorders (FAODs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fatty Acid Oxidation Disorders (FAODs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Fatty Acid Oxidation Disorders (FAODs) Overview

Fatty Acid Oxidation Disorders (FAODs) are a group of inherited metabolic conditions that result in an accumulation of fatty acids and a decrease in cell energy metabolism. Each fatty acid oxidation disorder is caused by a specific enzyme defect in the fatty acid metabolic pathway and has an impact on dietary and stored fat utilisation. The presentation of a FAOD varies depending on the disorder, but common elements may be observed and ultimately require similar treatment. Initial presentations of the FAODs in the neonatal period with severe symptoms include cardiomyopathy, while liver dysfunction and hypoketotic hypoglycemia are common during infancy and childhood. Fatty Acid Oxidation Disorders (FAODs) are all inherited in an autosomal recessive manner. Patients will have inherited two copies of a FAOD with a mutation or variant in the DNA sequence. Each pregnancy will have a one-in-four chance of a child being affected, a one-in-two chance of being an unaffected carrier, and a one-in-four chance of being unaffected and not a carrier.

• According to the study, there is an estimated collective incidence of 0.85 to 1.12 cases in every 5,000 to 10,000 births, although the individual prevalence varies significantly. MCAD is the most common of the fatty acid oxidation disorders, affecting one in every 10,000 to 20,000 births. LCHAD and VLCAD are rare disorders that affect one in every 100,000 births. There appears to be a mild form of SCAD deficiency that is quite common, but the clinical significance of this condition is unknown.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: